ArticleCancer management and research2025
Bevacizumab Efficacy and Tolerability in Patients with Metastatic Platinum-Sensitive Ovarian Cancer Beyond Progression.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: High recurrence rates and the emergence of resistance mechanisms in ovarian cancer necessitate exploring alternative therapeutic strategies except platinum-based chemotherapies. This has led to the development of bevacizumab, a recombinant humanized monoclonal antibody targeting VEGF. Nevertheless, the continuation of bevacizumab treatment initiated alongside chemotherapy, especially after disease progression, remains a topic of debate. Materials and Methods: Our study involved a single-center retrospective analysis of the medical records of patients diagnosed with stage 3 and 4 epithelial ovarian cancer between June 2011 and January 2023. All patients in our study were platinum-sensitive. Results: Patients with residual disease >1 cm following initial surgery had significantly worse median OS (p = 0.002). Post-progression, patients were divided into two groups based on whether bevacizumab was continued. More than half of the patients who continued treatment with bevacizumab and chemotherapy achieved a 5-year OS, which was statistically superior (p < 0.001). When comparing PFS between patients who did and did not receive bevacizumab in the second line following recurrence/progression, those treated with bevacizumab demonstrated a median PFS of 12.0 months (95% CI: 10.5-13.4), which was significantly better (p < 0.001). The hazard ratio for mortality in patients continuing bevacizumab treatment beyond progression was 0.11 (95% CI: 0.05-0.22) (p < 0.001). Conclusion: Many studies have shown the effectiveness and survival benefit of bevacizumab in epithelial ovarian cancer. In contrast, the literature offers limited studies addressing the survival benefits of continuing bevacizumab beyond disease progression. However, our study indicates that continuing bevacizumab beyond progression significantly contributes to both OS (p < 0.001) and PFS (p < 0.001). As larger studies with similar results to ours are conducted in the future, current guidelines may improve, and the decision to continue bevacizumab treatment after progression may become more evidence-based.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.